Medicare has finalized expanded coverage for TAVR, including certain asymptomatic patients with severe aortic stenosis, while ...
AstraZeneca and Daiichi Sankyo’s HER2-targeting ADC showed a PFS benefit in first-line treatment of HER2-mutant non-small ...
Strong PFS data and oral convenience may enable zipalertinib to compete against J&J’s bispecific Rybrevant in NSCLC patients ...
The US FDA approved the myostatin inhibitor Isembyld (apitegromab) on top of SMN-targeted therapies for spinal muscular ...
Peerbridge plans to introduce its newly FDA-cleared second-generation Cor MDx patch for detecting heart arrythmias to health ...
VDGH chief executive Martin Walger is putting his hopes on positive EU trilog outcomes regarding the IVDR and MDR amendments, ...
Sanofi will transition 20 mature medicines to German established products player Cheplapharm, including the off-patent blood ...
H3-targeted antibody-drug conjugate tambotatug pelitecan achieves overall survival and progression-free survival benefits in ...
Mike Davis used his first public address as permanent CDER director to outline realigned incentives that will favor ...
Guaranteeing better than standard of care for patients in the control arm and offering better efficacy analyses are among ...
The German health technology assessment of Amgen’s Blincyto indicates companies can fulfill evidentiary requirements, even ...
Key opinion leaders share their perspectives on the competitive dynamics reshaping the biopharma industry in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results